Caverject Injection, Powder, Lyophilized, For Solution
Product Images NDC 0009-7686

Product Visual Gallery

This gallery contains 28 technical images submitted to the FDA as part of the official labeling for Caverject (NDC 0009-7686). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pharmacia & Upjohn Company Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure A (Caverject 01)

An instructional diagram showing the top view of the penis with shaded areas indicating recommended injection sites for Caverject (Alprostadil) intracavernous injections.*

FDA Label Image

Figure B (Caverject 02)

An instructional anatomical diagram showing a cross-section of the penis, highlighting the corpora cavernosa. The image illustrates the correct 90-degree angle for intracavernous injection and marks areas where injection should be avoided, emphasizing safety for the use of Caverject (alprostadil) injection.*

FDA Label Image

Chemical Structure (Caverject 03)

Chemical structure of alprostadil, the active ingredient in Caverject injection. The diagram shows the molecular arrangement including hydroxyl groups and carboxyl functional groups characteristic of alprostadil.*

FDA Label Image

Logo (Caverject 04)

FDA Label Image

Logo (Caverject 05)

FDA Label Image

Figure A (Caverject 06)

An instructional diagram showing supplies needed to prepare a Caverject injection. It depicts a Caverject sterile powder vial, a diluent vial labeled 'DILUENT', a sterile syringe (1 to 3 mL), alcohol swabs, a 29 or 30 gauge one-half inch needle for injection, and a 21 to 27 gauge sterile needle for mixing the medicine. The image notes which items are not supplied with Caverject.*

FDA Label Image

Figure B (Caverject 07)

A labeled black and white line drawing illustrating the parts of a syringe assembly. The components shown are needle cap, needle, needle assembly, syringe cap, tip, barrel, plunger, and the main syringe body.*

FDA Label Image

Figure C (Caverject 08)

An instructional illustration depicting a hand peeling back adhesive tape from a syringe, likely demonstrating a step in the preparation or use of the injection device for Caverject (Alprostadil) intracavernous injection.*

FDA Label Image

Figure D (Caverject 09)

An instructional black-and-white illustration showing two hands opening a vial or ampule. One hand holds the vial securely while the other hand twists or peels open the top, indicated by an arrow showing the direction of removal.*

FDA Label Image

Figure E (Caverject 10)

Illustration showing preparation of a syringe by removing the syringe cap from the syringe tip. The image highlights the parts labeled as syringe cap and syringe tip, demonstrating how to ready the syringe for use.*

FDA Label Image

Figure F (Caverject 11)

An instructional line drawing demonstrating the preparation of a syringe for injection. It shows a hand holding a syringe and another hand using a piece of gauze or cloth to wipe the syringe tip, with an arrow indicating a twisting motion to attach or adjust the syringe components.*

FDA Label Image

Figure G (Caverject 12)

An instructional black-and-white line drawing illustrating a hand holding a small vial or bottle with a twist-off top, indicating the step to twist and remove the cap, commonly associated with preparing an injection.*

FDA Label Image

Figure H (Caverject 13)

An instructional illustration depicting hands preparing a syringe by removing the cap from the needle. The image shows the syringe held in one hand with the other hand pulling the protective needle cap upward.*

FDA Label Image

Figure I (Caverject 14)

An instructional line drawing showing two hands preparing an injection using a vial and a syringe. One hand holds the vial upside down while the other hand draws liquid into the syringe, indicated by an arrow pointing upward on the syringe plunger.*

FDA Label Image

Figure J (Caverject 15)

An instructional line drawing showing two hands preparing a syringe. One hand holds the syringe, while the other hand pulls back the plunger. Arrows indicate the direction of movement for the plunger, suggesting a step in preparation for injection. No text or branding is visible.*

FDA Label Image

Figure K (Caverject 16)

An instructional illustration showing hands drawing liquid into a syringe from a vial. The diagram includes a magnified detail indicating the syringe plunger position at the '1 mL' mark, with arrows guiding the proper movement of the plunger during liquid extraction.*

FDA Label Image

Figure L (Caverject 17)

An instructional black-and-white line drawing showing two hands preparing an injection. One hand holds a vial steady while the other hand inserts a syringe needle into the vial's rubber stopper. An arrow indicates the downward motion of the syringe needle into the vial. No text or brand information is visible in the image.*

FDA Label Image

Figure M (Caverject 18)

An instructional illustration showing a person preparing an injection. The image depicts hands drawing solution from a vial into a syringe, with arrows indicating the direction of movement for drawing the medication. It is related to the administration of an injectable pharmaceutical product.*

FDA Label Image

Figure N (Caverject 19)

An instructional illustration showing a hand drawing liquid from a vial into a syringe, demonstrating the preparation of Caverject (Alprostadil) injection for intracavernous use.*

FDA Label Image

Figure O (Caverject 20)

An anatomical illustration of the male genitalia highlighting the intracavernous area. The diagram shows the penis and surrounding structures, indicating the site of intracavernous injection for drug administration.*

FDA Label Image

Figure P (Caverject 21)

An instructional diagram showing a top side cross-section of the penis highlighting the corpora cavernosa. The image indicates the correct 90-degree angle for an intracavernosal injection, with a warning to avoid injecting near certain marked areas.*

FDA Label Image

Figure Q (Caverject 22)

An instructional illustration depicting the administration of an intracavernous injection. The image shows hands holding a syringe and preparing to inject into the base of the penis, demonstrating the injection site and technique relevant to the use of Caverject (alprostadil) injection.*

FDA Label Image

Figure R (Caverject 23)

An instructional line drawing illustrating the technique for injecting a solution into the penis using a syringe, depicting one hand holding the syringe with the plunger being pulled back and the other hand stabilizing the injection site. This is related to the intracavernous injection route for Caverject (alprostadil) powder for solution injection.*

FDA Label Image

Logo (Caverject 24)

FDA Label Image

Image Not Available (5 mcg)

Label for Caverject alprostadil for injection 20 mcg, a lyophilized powder for solution injection by Pharmacia & Upjohn Company LLC, Pfizer. It indicates intracavernosal route, single dose vial, and provides storage, dosing instructions, and preservative information.*

FDA Label Image

Image Not Available (10 mcg)

Caverject 20 mcg injection powder, lyophilized, for intracavernosal use only. The label shows Pfizer branding and specifies 6 single-dose vials per package. Distributed by Pharmacia & Upjohn Company LLC, the packaging includes dosage and storage instructions, ingredient amounts, and notes that the reconstituted solution is preservative-containing and must be used within 24 hours. The label also mentions no diluent is included and highlights the required route of administration.*

FDA Label Image

Principal Display Panel (20 mcg Vial Label)

Label for Caverject alprostadil for injection 40 mcg, an intracavernosal use only lyophilized powder for solution. The label includes storage instructions, dosage preparation details, and states it is a single dose vial by Pharmacia & Upjohn Company LLC, a Pfizer company.*

FDA Label Image

Principal Display Panel (20 mcg Vial Package)

Caverject 40 mcg injection lyophilized powder for solution, labeled for intracavernosal use only. The carton contains 6 single-dose vials. Distributed by Pharmacia & Upjohn Company LLC, a division of Pfizer Inc. The label includes storage instructions, reconstitution directions, and notes that the diluent should contain benzyl alcohol as a preservative and is not included in the package.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.